Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

Background and objective: Sacituzumab govitecan (SG), the first antibody-drug conjugate targeting human trophoblast cell-surface antigen 2 (Trop-2), has been approved by the Food and Drug Administration (FDA) for the treatment of advanced or metastatic breast cancer and urothelial cancer. However, t...

Full description

Bibliographic Details
Main Authors: Wensheng Liu, Qiong Du, Zihan Guo, Xuan Ye, Jiyong Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Pharmacology
Subjects:
sacituzumab govitecan
antibody-drug conjugate
Trop-2
pharmacovigilance
adverse event
FAERS
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1283247/full

Similar Items

Similar Items